Scholar Rock is trading $49.09, up +5.22%, as broader risk appetite supports equities.
- The move reflects an opening-week recovery in a broadly stronger market; the S&P 500 is up 1.01% and Nasdaq is up 1.59%.
- It follows recent post-approval profit-taking after FDA approval of ISEMBYLD and mixed analyst reactions, including Barclaysβ downgrade.
- No new company-specific catalyst was identified for September 21, 2026.